Previous 10 | Next 10 |
2024-03-20 09:02:02 ET Adverum Biotechnologies Inc (ADVM) announced stock split at a ratio of 1-for-10 on 2024-03-21 ... Full story available on KlickAnalytics.com
2024-03-19 16:04:27 ET Summary Ocular Therapeutics' stock has surged 184% in six months, driven by promising clinical assets in eye disease treatments. Dextenza's success illustrates Ocular's Elutyx technology potential, but Paxtrava faces tough competition and logistical challeng...
2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
2024-03-18 16:35:03 ET More on Adverum Biotechnologies Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies Read the full article on Seeking Alp...
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors...
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executi...
2024-02-22 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outl...
2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief execut...
2024-02-11 04:35:17 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash...
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 20...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...